Back to top
more

Soleno Therapeutics (SLNO)

(Delayed Data from NSDQ)

$56.86 USD

56.86
753,536

+0.47 (0.83%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $56.72 -0.14 (-0.25%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (92 out of 251)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Corcept's (CORT) Q1 Earnings & Revenues Fall Shy of Estimates

by Zacks Equity Research

Corcept's (CORT) earnings as well as revenues miss estimates in the first quarter of 2022.

Pacira's (PCRX) Q1 Earnings Miss Estimates, Revenues Rise Y/Y

by Zacks Equity Research

Pacira's (PCRX) earnings fall shy of estimates in the first quarter of 2022 while revenues beat the same.

Zoetis' (ZTS) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Zoetis' (ZTS) earnings and revenues trump estimates in the first quarter of 2022.

Down 13.9% in 4 Weeks, Here's Why Soleno Therapeutics, Inc. (SLNO) Looks Ripe for a Turnaround

by Zacks Equity Research

Soleno Therapeutics, Inc. (SLNO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Soleno Therapeutics (SLNO) Enters Oversold Territory

by Zacks Equity Research

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

Pacira (PCRX) Gets FDA Nod for Exparel in Pediatric Patients

by Zacks Equity Research

The FDA approves Pacira's (PCRX) Exparel for use in patients aged six years and older for single-dose infiltration to produce postsurgical local analgesia.

Catalyst (CPRX) Beats on Q4 Earnings, Revenues Rise Y/Y

by Zacks Equity Research

Catalyst's (CPRX) earnings and revenues beat estimates in the fourth quarter of 2020.

Soleno Therapeutics (SLNO) Is in Oversold Territory: What's Next?

by Zacks Equity Research

Soleno Therapeutics (SLNO) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock

Soleno Therapeutics' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Soleno Therapeutics.

Soleno (SLNO) in Focus: Stock Moves 6.3% Higher

by Zacks Equity Research

Soleno (SLNO) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

Soleno (SLNO) to report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

We expect Soleno (SLNO) to provide its clinical program updates when its releases second-quarter 2020 results.

Translate Bio (TBIO) in Focus: Stock Moves 11.7% Higher

by Zacks Equity Research

Translate Bio (TBIO) saw a big move last session, as its shares jumped nearly 12% on the day, amid huge volumes.

Soleno (SLNO) Looks Good: Stock Adds 6.8% in Session

by Zacks Equity Research

Soleno (SLNO) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

Soleno Therapeutics, Inc. (SLNO) Upgraded to Strong Buy: What Does It Mean for the Stock?

by Zacks Equity Research

Soleno Therapeutics, Inc. (SLNO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Implied Volatility Surging for Soleno Therapeutics (SLNO) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Soleno Therapeutics (SLNO) stock based on the movements in the options market lately.

Jazz Pharma (JAZZ) Surpasses Q4 Earnings & Sales Estimates

by Zacks Equity Research

Jazz Pharmaceuticals (JAZZ) beats fourth-quarter 2019 earnings and revenue estimates. It issues guidance for 2020.

Soleno (SLNO) Ends Enrollment in Prader-Willi Syndrome Study

by Zacks Equity Research

Soleno Therapeutics (SLNO) achieves enrollment target in the phase III study evaluating Diazoxide Choline Controlled-Release tablets for treating patients with Prader-Willi Syndrome. Stock up.

Capnia, Inc. (SLNO) Upgraded to Strong Buy: Here's What You Should Know

by Zacks Equity Research

Capnia, Inc. (SLNO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

FDA Accepts Neurocrine's NDA for Parkinson's Disease Drug

by Zacks Equity Research

The FDA accepts Neurocrine's (NBIX) NDA for opicapone, developed as an adjunctive treatment to levodopa/carbidopa for patients with Parkinson's disease, who currently experience OFF episodes.

La Jolla (LJPC) Secures Positive CHMP Opinion for Giapreza

by Zacks Equity Research

The CHMP recommends La Jolla's (LJPC) marketing application for Giapreza to treat refractory hypotension in adult patients with septic or distributive shock.

Will Capnia to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Capnia.

Soleno Therapeutics (SLNO) to Post Q1 Earnings: What's Up?

by Zacks Equity Research

During Soleno Therapeutics' (SLNO) Q1 conference call, investor focus will be on its progress with the ongoing study on DCCR tablets, developed for the treatment of Prader-Willi syndrome.

Kinjel Shah headshot

Small Drug Stocks Outlook: Near-Term Prospects Encouraging

by Kinjel Shah

Successful innovation resulting in new drug approvals, important advances in clinical studies, frequent collaboration and M&A activity keep small drugmakers afloat in a competitive market.

Will Capnia Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Capnia.

Are You Looking for a Top Momentum Pick? Why Capnia, Inc. (SLNO) is a Great Choice

by Zacks Equity Research

Does Capnia, Inc. (SLNO) have what it takes to be a top stock pick for momentum investors? Let's find out.